Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of vemurafenib in BRAF V600-mutant metastatic melanoma
NL-OMON39617Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vemurafenib in melanoma, sponsored by Roche. Primary endpoint: Safety and tolerability. Started Mar 2011; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON39617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39617.